Current Report ESPI 12/2025

The Management Board of Ryvu Therapeutics S.A., with its registered office in Kraków (the “Company”), hereby informs that on May 2, 2025 it received a notification from TFI Allianz Polska S.A., acting on behalf of the following funds: Allianz FIO, Allianz Inwestycje SFIO, Allianz Plan Emerytalny SFIO, and Bezpieczna Jesień SFIO (the “Funds”), prepared in accordance with Article 69(1)(1) and Article 87(1)(2)(a) of the Act of 29 July 2005 on Public Offering, Conditions Governing the Introduction of Financial Instruments to Organized Trading, and Public Companies, regarding a decrease below the 5% threshold of the total number of votes at the Company’s General Meeting.

According to the content of the notification, as a result of a sale transaction of the Company’s shares carried out on 28 April 2025 (settlement date: 30 April 2025), the total share of the Funds in the total number of votes at the General Meeting of the Company decreased below the 5% threshold and currently amounts to 4.96%.

The full content of the notification is attached to this report.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

 

Legal basis: Article 70 point 1 of the Public Offering Act

Representatives of the Issuer:

• Paweł Przewięźlikowski – President of the Management Board
• Kamil Sitarz – Member of the Management Board